Literature DB >> 3586568

[IgG antibodies to toxic shock syndrome toxin-1 (TSST-1) in human sera].

N Dickgiesser, B Kustermann.   

Abstract

IgG antibodies against toxic shock syndrome toxin-1 (TSST-1) in 2002 human sera were determined using an enzyme-linked immunosorbent assay. The results indicate a very early common exposure to TSST-1 in German males and females. The antibody titers are increasing up to the age of 20. They continue to increase further from the mid-thirties, reaching a peak level in the mid-fifties. Toxic shock syndrome is rarely described in Germany. It is possible, therefore, that most of the infections with TSST-1 producing S. aureus are of a subclinical nature. An atypical, less dramatic course than the commonly known toxic shock syndrome is also discussed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3586568     DOI: 10.1007/bf01773444

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  8 in total

1.  [IgG antibodies against toxic shock syndrome toxin 1 in human immunoglobulins].

Authors:  N Dickgiesser; B Kustermann
Journal:  Klin Wochenschr       Date:  1986-07-15

2.  Development of serum antibody to toxic shock toxin among individuals with toxic shock syndrome in Wisconsin.

Authors:  S J Stolz; J P Davis; J M Vergeront; B A Crass; P J Chesney; P J Wand; M S Bergdoll
Journal:  J Infect Dis       Date:  1985-05       Impact factor: 5.226

3.  Expression of the cloned toxic shock syndrome toxin 1 gene (tst) in vivo with a rabbit uterine model.

Authors:  J C de Azavedo; T J Foster; P J Hartigan; J P Arbuthnott; M O'Reilly; B N Kreiswirth; R P Novick
Journal:  Infect Immun       Date:  1985-10       Impact factor: 3.441

4.  Serological response to toxic shock syndrome toxin in Staphylococcus aureus infected patients and healthy controls.

Authors:  B Christensson; S A Hedström
Journal:  Acta Pathol Microbiol Immunol Scand B       Date:  1985-04

5.  Association of high levels of serum antibody to staphylococcal toxic shock antigen with nasal carriage of toxic shock antigen-producing strains of Staphylococcus aureus.

Authors:  H L Ritz; J J Kirkland; G G Bond; E K Warner; G P Petty
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

6.  An enterotoxin-like protein in Staphylococcus aureus strains from patients with toxic shock syndrome.

Authors:  M S Bergdoll; B A Crass; R F Reiser; R N Robbins; A C Lee; P J Chesney; J P Davis; J M Vergeront; P J Wand
Journal:  Ann Intern Med       Date:  1982-06       Impact factor: 25.391

7.  Prevalence of serum antibody to staphylococcal enterotoxin F among Wisconsin residents: implications for toxic-shock syndrome.

Authors:  J M Vergeront; S J Stolz; B A Crass; D B Nelson; J P Davis; M S Bergdoll
Journal:  J Infect Dis       Date:  1983-10       Impact factor: 5.226

8.  Antibody responses to toxic-shock-syndrome (TSS) toxin by patients with TSS and by healthy staphylococcal carriers.

Authors:  P F Bonventre; C Linnemann; L S Weckbach; J L Staneck; C R Buncher; E Vigdorth; H Ritz; D Archer; B Smith
Journal:  J Infect Dis       Date:  1984-11       Impact factor: 5.226

  8 in total
  3 in total

1.  [IgM antibodies to toxic shock syndrome toxin-1 in human sera and human immunoglobulins].

Authors:  N Dickgiesser; F Düzgün
Journal:  Klin Wochenschr       Date:  1988-01-04

2.  [Special features of intensive care of toxic shock syndrome. Review and case report of a TSST-1 associated toxic-shock syndrome with adult respiratory distress syndrome and multiple organ failure from a staphylococcal panaritium].

Authors:  C Lang; H Behnke; J Bittersohl; L Eberhart; E Walthers; F Sommer; H Wulf; G Geldner
Journal:  Anaesthesist       Date:  2003-09       Impact factor: 1.041

3.  Prevalence of toxic shock syndrome toxin 1 (TSST-1)-producing strains of Staphylococcus aureus and antibody to TSST-1 among healthy Japanese women.

Authors:  Jeffrey Parsonnet; Richard V Goering; Melanie A Hansmann; Michaelle B Jones; Kumiko Ohtagaki; Catherine C Davis; Kyoichi Totsuka
Journal:  J Clin Microbiol       Date:  2008-06-11       Impact factor: 5.948

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.